Mutations of the cohesin complex in human cancer were first discovered ~10 years ago. Since then, researchers worldwide have demonstrated that cohesin is among the most commonly mutated protein complexes in cancer. Inactivating mutations in genes encoding cohesin subunits are common in bladder cancers, paediatric sarcomas, leukaemias, brain tumours and other cancer types. Also in those 10 years, the prevailing view of the functions of cohesin in cell biology has undergone a revolutionary transformation. Initially, the predominant view of cohesin was as a ring that encircled and cohered replicated chromosomes until its cleavage triggered the metaphase-to-anaphase transition. As such, early studies focused on the role of tumour-derived cohesin mutations in the fidelity of chromosome segregation and aneuploidy. However, over the past 5 years the cohesin field has shifted dramatically, and research now focuses on the primary role of cohesin in generating, maintaining and regulating the intra-chromosomal DNA looping events that modulate 3D genome organization and gene expression. This Review focuses on recent discoveries in the cohesin field that provide insight into the role of cohesin inactivation in cancer pathogenesis, and opportunities for exploiting these findings for the clinical benefit of patients with cohesin-mutant cancers.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Michaelis, C., Ciosk, R. & Nasmyth, K. Cohesins: chromosomal proteins that prevent premature separation of sister chromatids. Cell 91, 35–45 (1997).
Guacci, V., Koshland, D. & Strunnikov, A. A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in S. cerevisiae. Cell 91, 47–57 (1997). Together with Michaelis et al. (1997), this paper reports the initial discovery of the cohesin complex in yeast.
Losada, A., Hirano, M. & Hirano, T. Identification of Xenopus SMC protein complexes required for sister chromatid cohesion. Genes. Dev. 12, 1986–1997 (1998).
Peters, J. M. & Nishiyama, T. Sister chromatid cohesion. Cold Spring Harb. Perspect. Biol 4, a011130 (2012).
Haarhuis, J. H., Elbatsh, A. M. & Rowland, B. D. Cohesin and its regulation: on the logic of X-shaped chromosomes. Dev. Cell 31, 7–18 (2014).
Barber, T. D. et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc. Natl Acad. Sci. USA 105, 3443–3448 (2008).
Rocquain, J. et al. Alteration of cohesin genes in myeloid diseases. Am. J. Hematol. 85, 717–719 (2010).
Solomon, D. A. et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333, 1039–1043 (2011). This paper is the first to report STAG2 mutations in human cancer.
Krantz, I. D. et al. Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat. Genet. 36, 631–635 (2004).
Tonkin, E. T., Wang, T. J., Lisgo, S., Bamshad, M. J. & Strachan, T. NIPBL, encoding a homolog of fungal Scc2-type sister chromatid cohesion proteins and fly Nipped-B, is mutated in Cornelia de Lange syndrome. Nat. Genet. 36, 636–641 (2004).
Nasmyth, K. Segregating sister genomes: the molecular biology of chromosome separation. Science 297, 559–565 (2002).
Zhang, N. et al. Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 13033–13038 (2008).
Remeseiro, S. et al. Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres. EMBO J. 31, 2076–2089 (2012).
Schubert, V. et al. Cohesin gene defects may impair sister chromatid alignment and genome stability in Arabidopsis thaliana. Chromosoma 118, 591–605 (2009).
Covo, S., Puccia, C. M., Argueso, J. L., Gordenin, D. A. & Resnick, M. A. The sister chromatid cohesion pathway suppresses multiple chromosome gain and chromosome amplification. Genetics 196, 373–384 (2014).
Hodges, C. A., Revenkova, E., Jessberger, R., Hassold, T. J. & Hunt, P. A. SMC1β-deficient female mice provide evidence that cohesins are a missing link in age-related nondisjunction. Nat. Genet. 37, 1351–1355 (2005).
Chiang, T., Duncan, F. E., Schindler, K., Schultz, R. M. & Lampson, M. A. Evidence that weakened centromere cohesion is a leading cause of age-related aneuploidy in oocytes. Curr. Biol. 20, 1522–1528 (2010).
Kleyman, M., Kabeche, L. & Compton, D. A. STAG2 promotes error correction in mitosis by regulating kinetochore-microtubule attachments. J. Cell Sci. 127, 4225–4233 (2014).
Li, X. et al. Loss of STAG2 causes aneuploidy in normal human bladder cells. Genet. Mol. Res. 14, 2638–2646 (2015).
Balbás-Martínez, C. et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat. Genet. 45, 1464–1469 (2013).
Kon, A. et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232–1237 (2013). This paper is the first to demonstrate that genes encoding cohesin subunits are commonly inactivated by mutations in myeloid leukaemia.
Yoshida, K. et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat. Genet. 45, 1293–1299 (2013).
Crompton, B. D. et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 4, 1326–1341 (2014).
Brohl, A. S. et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLOS Genet. 10, e1004475 (2014).
Tirode, F. et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4, 1342–1353 (2014). Together with Crompton et al. (2014) and Brohl et al. (2014), this paper demonstrates that STAG2 is the most commonly mutated gene in Ewing sarcoma other than the tumour-defining EWS–FLI translocation.
Castronovo, P. et al. Premature chromatid separation is not a useful diagnostic marker for Cornelia de Lange syndrome. Chromosome Res. 17, 763–771 (2009).
Kim, J. S. et al. Intact cohesion, anaphase, and chromosome segregation in human cells harboring tumor-derived mutations in STAG2. PLOS Genet. 12, e1005865 (2016).
DeMare, L. E. et al. The genomic landscape of cohesin-associated chromatin interactions. Genome Res. 23, 1224–1234 (2013).
Lee, B. K. & Iyer, V. R. Genome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation. J. Biol. Chem. 287, 30906–30913 (2012).
Wutz, G. et al. Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins. EMBO J. 36, 3573–3599 (2017).
Busslinger, G. A. et al. Cohesin is positioned in mammalian genomes by transcription, CTCF and Wapl. Nature 544, 503–507 (2017).
Viny, A. D. et al. Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation. Cell Stem Cell 25, 682–696 (2019).
Casa, V. et al. Redundant and specific roles of cohesin STAG subunits in chromatin looping and transcription control. Genome Res. 30, 515–527 (2020).
Rao, S. S. P. et al. Cohesin loss eliminates all loop domains. Cell 171, 305–320 (2017). This paper is among the first to demonstrate that cohesin is required to demarcate and anchor the boundaries of self-interacting contiguous regions of chromosomes known as TADs.
Schwarzer, W. et al. Two independent modes of chromatin organization revealed by cohesin removal. Nature 551, 51–56 (2017).
Haarhuis, J. H. I. et al. The cohesin release factor WAPL restricts chromatin loop extension. Cell 169, 693–707 (2017).
Kim, Y., Shi, Z., Zhang, H., Finkelstein, I. J. & Yu, H. Human cohesin compacts DNA by loop extrusion. Science 366, 1345–1349 (2019).
Davidson, I. F. et al. DNA loop extrusion by human cohesin. Science 366, 1338–1345 (2019). Together with Kim et al. (Science, 2019), this paper is the first to demonstrate that purified human cohesin functions as a catalytic engine for loop extrusion in vitro.
Kojic, A. et al. Distinct roles of cohesin-SA1 and cohesin-SA2 in 3D chromosome organization. Nat. Struct. Mol. Biol. 25, 496–504 (2018).
Cuadrado, A. et al. Specific contributions of cohesin-SA1 and cohesin-SA2 to TADs and polycomb domains in embryonic stem cells. Cell Rep. 27, 3500–3510 (2019).
Wutz, G. et al. ESCO1 and CTCF enable formation of long chromatin loops by protecting cohesinSTAG1 from WAPL. eLife 9, e52091 (2020).
Lu, L., et al. (2019) Robust Hi-C chromatin loop maps in human neurogenesis and brain tissues at high-resolution. bioRxiv https://doi.org/10.1101/744540 (2019).
Xiao, T., Wallace, J. & Felsenfeld, G. Specific sites in the C terminus of CTCF interact with the SA2 subunit of the cohesin complex and are required for cohesin-dependent insulation activity. Mol. Cell. Biol. 31, 2174–2183 (2011).
Ghirlando, R. & Felsenfeld, G. CTCF: making the right connections. Genes. Dev. 30, 881–891 (2016).
Ding, L. W. et al. Mutational landscape of pediatric acute lymphoblastic leukemia. Cancer Res. 77, 390–400 (2017).
Marshall, A. D. et al. CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. Oncogene 36, 4100–4110 (2017).
Kemp, C. J. et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep. 7, 1020–1029 (2014).
Katainen, R. et al. CTCF/cohesin-binding sites are frequently mutated in cancer. Nat. Genet. 47, 818–821 (2015). This paper is the first to demonstrate that cohesin/CTCF DNA binding sites are mutated in cancer cells more frequently than would be expected by chance alone, emphasizing that alterations in cohesin-mediated 3D genome organization may be a fundamental feature of diverse cancer types.
Guo, Y. A. et al. Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers. Nat. Commun. 9, 1520 (2018).
Liu, E. M. et al. Identification of cancer drivers at CTCF insulators in 1,962 whole genomes. Cell Syst. 8, 446–455 (2019).
Kagey, M. H. et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 467, 430–435 (2010).
Mondal, G., Stevers, M., Goode, B., Ashworth, A. & Solomon, D. A. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat. Commun. 10, 1686 (2019).
Mullenders, J. et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J. Exp. Med. 212, 1833–1850 (2015).
Mazumdar, C. et al. Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell 17, 675–688 (2015).
Viny, A. D. et al. Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J. Exp. Med. 212, 1819–1832 (2015). Together with Mullenders et al. (2015) and Mazumdar et al. (2015), this paper is the first to demonstrate that inactivation of cohesin dramatically alters the stemness and pluripotentiality of stem cells, identifying a primary role for cohesin in the regulation of cellular differentiation.
Galeev, R. et al. Genome-wide RNAi screen identifies cohesin genes as modifiers of renewal and differentiation in human HSCs. Cell Rep. 14, 2988–3000 (2016).
Tothova, Z. et al. Multiplex CRISPR/Cas9-based genome editing in human hematopoietic stem cells models clonal hematopoiesis and myeloid neoplasia. Cell Stem Cell 21, 547–555 (2017).
Cuartero, S. et al. Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation. Nat. Immunol. 19, 932–941 (2018).
Sasca, D. et al. Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. Blood 134, 2195–2208 (2019).
Lavagnolli, T. et al. Initiation and maintenance of pluripotency gene expression in the absence of cohesin. Genes. Dev. 29, 23–38 (2015).
Chen, Z. et al. Cohesin-mediated NF-κB signaling limits hematopoietic stem cell self-renewal in aging and inflammation. J. Exp. Med. 216, 152–175 (2019).
Yun, J. et al. Dynamic cohesin-mediated chromatin architecture controls epithelial–mesenchymal plasticity in cancer. EMBO Rep. 17, 1343–1359 (2016).
O’Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613–623 (2017).
Canudas, S. & Smith, S. Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells. J. Cell Biol. 187, 165–173 (2009).
van der Lelij, P. et al. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. eLife 6, e26980 (2017).
Benedetti, L., Cereda, M., Monteverde, L., Desai, N. & Ciccarelli, F. D. Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1. Oncotarget 8, 37619–37632 (2017). Together with van der Lelij et al. (2017), this paper is the first to demonstrate that inactivation of STAG2 generates an absolute cellular dependency on its orthologue STAG1.
Liu, Y. et al. Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J. Clin. Invest. 128, 2951–2965 (2018).
Bai, P. Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol. Cell. 58, 947–958 (2015).
McLellan, J. L. et al. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLOS Genet. 8, e1002574 (2012).
Bailey, M. L. et al. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol. Cancer Ther. 13, 724–732 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03974217 (2019).
Solomon, D. A. et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat. Genet. 45, 1428–1430 (2013).
Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459–1463 (2013). Together with Balbás-Martínez et al. (2013) and Solomon et al. (2013), this paper demonstrates that cohesin gene mutations are among the most common genetic events in the pathogenesis of early-stage bladder cancers.
Taylor, C. F., Platt, F. M., Hurst, C. D., Thygesen, H. H. & Knowles, M. A. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum. Mol. Genet. 23, 1964–1974 (2014).
Lelo, A. et al. STAG2 Is a biomarker for prediction of recurrence and progression in papillary non-muscle-invasive bladder cancer. Clin. Cancer Res. 24, 4145–4153 (2018).
Qiao, Y., Zhu, X., Li, A., Yang, S. & Zhang, J. Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer. Tumour Biol. 37, 10279–10286 (2016).
Tsai, C. H. et al. Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer J. 7, 663 (2017).
Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
Thol, F. et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 123, 914–920 (2014).
Shen, C. H. et al. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat. Med. 22, 1056–1061 (2016).
Sundaramoorthy, S., Vázquez-Novelle, M. D., Lekomtsev, S., Howell, M. & Petronczki, M. Functional genomics identifies a requirement of pre-mRNA splicing factors for sister chromatid cohesion. EMBO J. 33, 2623–2642 (2014).
van der Lelij, P. et al. SNW1 enables sister chromatid cohesion by mediating the splicing of sororin and APC2 pre-mRNAs. EMBO J. 33, 2643–2658 (2014).
Watrin, E., Demidova, M., Watrin, T., Hu, Z. & Prigent, C. Sororin pre-mRNA splicing is required for proper sister chromatid cohesion in human cells. EMBO Rep. 15, 948–955 (2014).
Oka, Y. et al. UBL5 is essential for pre-mRNA splicing and sister chromatid cohesion in human cells. EMBO Rep. 15, 956–964 (2014).
Kim, J. S. et al. Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression. J. Biol. Chem. 294, 8760–8772 (2019).
McCracken, S. et al. Proteomic analysis of SRm160-containing complexes reveals a conserved association with cohesin. J. Biol. Chem. 280, 42227–42236 (2005).
Meisenberg, C. et al. Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. Mol. Cell. 73, 212–223 (2019).
Takahashi, T. S., Yiu, P., Chou, M. F., Gygi, S. & Walter, J. C. Recruitment of Xenopus Scc2 and cohesin to chromatin requires the pre-replication complex. Nat. Cell Biol. 6, 991–996 (2004).
Gillespie, P. J. & Hirano, T. Scc2 couples replication licensing to sister chromatid cohesion in Xenopus egg extracts. Curr. Biol. 14, 1598–1603 (2004).
Zheng, G., Kanchwala, M., Xing, C. & Yu, H. MCM2-7-dependent cohesin loading during S phase promotes sister-chromatid cohesion. eLife 7, e33920 (2018).
Ivanov, M. P. et al. The replicative helicase MCM recruits cohesin acetyltransferase ESCO2 to mediate centromeric sister chromatid cohesion. EMBO J. 37, e97150 (2018).
Terret, M. E., Sherwood, R., Rahman, S., Qin, J. & Jallepalli, P. V. Cohesin acetylation speeds the replication fork. Nature 462, 231–234 (2009).
Guillou, E. et al. Cohesin organizes chromatin loops at DNA replication factories. Genes. Dev. 24, 2812–2822 (2010).
Benedict, B. et al. WAPL-dependent repair of damaged DNA replication forks underlies oncogene-induced loss of sister chromatid cohesion. Dev. Cell 52, 683–698.e7 (2020).
Loubiere, V., Martinez, A. M. & Cavalli, G. Cell fate and developmental regulation dynamics by polycomb proteins and 3D genome architecture. Bioessays 41, e1800222 (2019).
Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).
Jain, P. & Di Croce, L. Mutations and deletions of PRC2 in prostate cancer. Bioessays 38, 446–454 (2016).
Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128–134 (2016).
Cunningham, M. D. et al. Wapl antagonizes cohesin binding and promotes Polycomb-group silencing in Drosophila. Development 139, 4172–4179 (2012).
Schaaf, C. A. et al. Cohesin and polycomb proteins functionally interact to control transcription at silenced and active genes. PLOS Genet. 9, e1003560 (2013).
Rhodes, J. D. P. et al. Cohesin disrupts polycomb-dependent chromosome interactions in embryonic stem cells. Cell Rep. 30, 820–835.e10 (2020).
Du, Z. et al. Polycomb group proteins regulate chromatin architecture in mouse oocytes and early embryos. Mol. Cell 77, 825–839.e7 (2020).
Stelloh, C. et al. The cohesin-associated protein Wapal is required for proper polycomb-mediated gene silencing. Epigenetics Chromatin 9, 14 (2016).
Sedeño Cacciatore, Á. & Rowland, B. D. Loop formation by SMC complexes: turning heads, bending elbows, and fixed anchors. Curr. Opin. Genet. Dev. 55, 11–18 (2019).
Walter, M. J. et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366, 1090–1098 (2012).
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Cancer Genome Atlas Research Network. et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
Walter, M. J. et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275–1282 (2013).
Thota, S. et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 124, 1790–1798 (2014).
Cancer Genome Atlas Research Network. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462–477 (2013).
Ceccarelli, M. et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550–563 (2016).
Musio, A. et al. X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. Nat. Genet. 38, 528–530 (2006).
Deardorff, M. A. et al. Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. Am. J. Hum. Genet. 80, 485–494 (2007).
Deardorff, M. A. et al. RAD21 mutations cause a human cohesinopathy. Am. J. Hum. Genet. 90, 1014–1027 (2012).
Yuan, B. et al. Clinical exome sequencing reveals locus heterogeneity and phenotypic variability of cohesinopathies. Genet. Med. 21, 663–675 (2019).
Zakari, M., Yuen, K. & Gerton, J. L. Etiology and pathogenesis of the cohesinopathies. Wiley Interdiscip. Rev. Dev. Biol. 4, 489–504 (2015).
Ronan, J. L., Wu, W. & Crabtree, G. R. From neural development to cognition: unexpected roles for chromatin. Nat. Rev. Genet. 14, 347–359 (2013).
Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592–601 (2013).
Tsurusaki, Y. et al. Mutations affecting components of the SWI/SNF complex cause Coffin–Siris syndrome. Nat. Genet. 44, 376–378 (2012).
Bögershausen, N. & Wollnik, B. Mutational landscapes and phenotypic spectrum of SWI/SNF-related intellectual disability disorders. Front. Mol. Neurosci. 11, 252 (2018).
Hoischen, A., Krumm, N. & Eichler, E. E. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat. Neurosci. 17, 764–772 (2014).
Muñoz, S., Minamino, M., Casas-Delucchi, C. S., Patel, H. & Uhlmann, F. A role for chromatin remodeling in cohesin loading onto chromosomes. Mol. Cell 74, 664–673.e5 (2019).
Lieberman-Aiden, E. et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326, 289–293 (2009).
Dekker, J., Marti-Renom, M. A. & Mirny, L. A. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. Nat. Rev. Genet. 14, 390–403 (2013).
Rowley, M. J. & Corces, V. G. Organizational principles of 3D genome architecture. Nat. Rev. Genet. 19, 789–800 (2018).
Mirny, L. A., Imakaev, M. & Abdennur, N. Two major mechanisms of chromosome organization. Curr. Opin. Cell. Biol. 58, 142–152 (2019).
Szabo, Q., Bantignies, F. & Cavalli, G. Principles of genome folding into topologically associating domains. Sci. Adv. 5, eaaw1668 (2019).
Hassler, M., Shaltiel, I. A. & Haering, C. H. Towards a unified model of SMC complex function. Curr. Biol. 28, R1266–R1281 (2018).
Dixon, J. R. et al. Chromatin architecture reorganization during stem cell differentiation. Nature 518, 331–336 (2015).
Cohesin cancer biology research in the T.W. laboratory is funded by NIH/National Cancer Institute (NCI) grant R01CA169345 and the Hyundai Hope on Wheels Foundation. The Lombardi Comprehensive Cancer Center is funded by NIH/NCI Cancer Center Support Grant P30CA051008.
The author declares no competing interests.
Peer review information
Nature Reviews Cancer thanks F. X. Real, A. Viny and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Chromosomal instability
The condition when cells have an abnormally high rate of mis-segregation of replicated chromosomes to daughter cells in mitosis. Results in aneuploidy.
The presence of an abnormal number of chromosomes in a cell, generally due to aberrant segregation of replicated chromosomes to daughter cells in mitosis.
- Chromatin immunoprecipitation-sequencing
A technique that combines chromatin immunoprecipitation (ChIP) with next-generation DNA sequencing to comprehensively identify, in an unbiased way, all of the genomic binding sites of chromatin-associated proteins. Often referred to as ChIP-seq.
- Haematopoietic stem and progenitor cells
(HSPCs). Multipotent, self-renewing adult stem cells that give rise to all types of differentiated blood cells in the lymphoid and myeloid lineages. HSPCs are found primarily in the bone marrow of adults, but are also found in umbilical cord blood and in peripheral blood.
- Auxin-inducible degron
A 68-amino-acid tag that, when added to an endogenous protein via gene editing, makes it possible to rapidly and completely degrade the tagged protein by adding auxin to the culture medium.
(High-throughput chromosome conformation capture). A next-generation DNA sequencing-based technique that makes it possible to comprehensively identify, in an unbiased way, regions of the genome that tend to co-localize in the 3D space comprising the interior of the nucleus.
- 3D genome organization
The 3D structure of chromosomes and their relative positioning in the nucleus. Sometimes also referred to as nuclear organization.
One of the two alleles of a gene is inactivated by mutation, resulting in a pathology such as cancer. Generally used to refer to tumour suppressor genes in which inactivation of one allele produces cancer, whereas inactivation of both alleles is lethal to the cell.
Measurable biological substances, such as DNA, RNA or protein, that provide predictive information about a patient’s likely clinical outcome.
- Synthetic lethality
The simultaneous inactivation of two gene products results in cell death, whereas inactivation of only one of the gene products does not. When applied to anticancer drug discovery, one of the inactivated proteins is encoded by a mutated tumour suppressor gene and the other protein is inactivated via pharmacological inhibition.
About this article
Cite this article
Waldman, T. Emerging themes in cohesin cancer biology. Nat Rev Cancer 20, 504–515 (2020). https://doi.org/10.1038/s41568-020-0270-1
International Journal of Molecular Sciences (2020)